secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001213900-24-017542
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital receives Nasdaq deficiency notice for MVLS below $50M; 180 days to comply
--------------------------------------------------------------------------------

- Nasdaq letter on Feb 22, 2024 cites MVLS below $50M for 30 consecutive days, violating Rule 5450(b)(2)(A).
- Also flagged non-compliance with total assets/revenue test under Rule 5450(b)(3)(A).
- Company has until Aug 20, 2024 to regain compliance by closing MVLS at or above $50M for 10 consecutive days.
- If unable, may transfer to Nasdaq Capital Market or face delisting; appeal rights available.
- Company will monitor MVLS and evaluate options; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024017542/0001213900-24-017542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024017542/ea0200805-8k_denalicap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-017542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer